Export financials
Quotient Limited (QTNT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Quotient Limited Balance Sheet 2022-2011 | QTNT
Brief overview of Quotient Limited's balance sheet structure
The comparison uses five available annual reports from the 2018–2022 interval.
Assets reached $194 million, compared with $123.8 million at the beginning. Growth of +56.6% and CAGR near 11.9% show active expansion.
Liabilities expanded faster than the asset base, +144.2% versus +56.6%. Debt-service capacity deserves attention.
Shareholders' capital is negative, making the balance sheet dependent on consistent debt servicing capacity.
Cash equals 33.5% of the balance sheet, compared with 16.3% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$725 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
What the balance sheet shows
Quotient Limited's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Quotient Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
172 M | 78.6 M | 145 M | 116 M | 63.8 M | 79.2 M | -14.1 M | -22.5 M | 7.91 M | -1.22 M | -1.26 M | - |
Long Term Debt |
233 M | 121 M | 145 M | 120 M | 84 M | 84 M | 29 M | 10.5 M | 15.1 M | 3 M | 3 M | - |
Long Term Debt Current |
3.54 M | 3.45 M | 3.31 M | - | - | - | 1 M | 4.5 M | - | - | - | - |
Total Non Current Liabilities |
- | - | 201 M | 151 M | 111 M | 104 M | 51.7 M | 28 M | 48.4 M | 31.3 M | 26.8 M | - |
Total Current Liabilities |
32.8 M | 59.5 M | 50.4 M | 25.4 M | 27.1 M | 29.7 M | 21.4 M | 54.8 M | 12.9 M | - | - | - |
Total Liabilities |
338 M | 255 M | 244 M | 176 M | 138 M | 134 M | 73 M | 81.8 M | 30.6 M | 36 M | 31 M | - |
Retained Earnings |
-725 M | -600 M | -561 M | -381 M | -276 M | -193 M | -108 M | -74.4 M | -15.3 M | -5.13 M | -416 K | - |
Total Assets |
194 M | 220 M | 247 M | 178 M | 124 M | 110 M | 120 M | 80.2 M | 29.8 M | 12.9 M | 12.4 M | - |
Cash and Cash Equivalents |
65.1 M | 45.7 M | 3.4 M | 4.1 M | 20.2 M | 4.75 M | 44.1 M | 37.5 M | 7.19 M | 4.22 M | - | - |
Book Value |
-144 M | -35.6 M | 2.24 M | 1.71 M | -14.6 M | -24.1 M | 46.7 M | -1.62 M | -773 K | -23.1 M | -18.7 M | - |
Total Shareholders Equity |
-144 M | -35.6 M | -8.49 M | 709 K | -15.2 M | -24.1 M | 46.7 M | -1.62 M | -31.5 M | -23.1 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Quotient Limited
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
240 M | 221 M | 236 M | 240 M | 229 M | 232 M | 103 M | 229 M | 121 M | 133 M | 145 M | 121 M | 145 M | 145 M | 145 M | 145 M | 120 M | 110 M | 110 M | 120 M | 110 M | 110 M | 84 M | 84 M | 84 M | 84 M | 84 M | 84 M | 30 M | 30 M | 9 M | 30 M | 12.2 M | 13.7 M | 15.2 M | 12.2 M | 13.7 M | 15.2 M | 15.1 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
328 M | 310 M | 326 M | 328 M | 334 M | 335 M | 338 M | 334 M | 238 M | 238 M | 231 M | 244 M | 230 M | 224 M | 215 M | 230 M | 166 M | 169 M | 167 M | 166 M | 169 M | 167 M | 138 M | 134 M | 134 M | 139 M | 134 M | 129 M | 63.4 M | 74.8 M | 81.9 M | 63.4 M | 74.5 M | 38.5 M | 35.1 M | 74.5 M | 38.5 M | 35.1 M | 30.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-823 M | -810 M | -764 M | -823 M | -699 M | -654 M | -627 M | -699 M | -554 M | -524 M | -509 M | -561 M | -459 M | -431 M | -404 M | -459 M | -354 M | -328 M | -301 M | -354 M | -328 M | -301 M | -276 M | -256 M | -256 M | -235 M | -214 M | -173 M | -98.7 M | -88.9 M | -84.5 M | -98.7 M | -71.9 M | -29.6 M | -17.9 M | -71.9 M | -29.6 M | -17.9 M | -15.3 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
119 M | 128 M | 175 M | 119 M | 209 M | 250 M | 277 M | 209 M | 246 M | 272 M | 201 M | 247 M | 248 M | 177 M | 193 M | 248 M | 191 M | 155 M | 131 M | 191 M | 155 M | 131 M | 124 M | 138 M | 138 M | 122 M | 139 M | 124 M | 89.6 M | 84.4 M | 73.6 M | 89.6 M | 66.6 M | 48.5 M | 58.5 M | 66.6 M | 48.5 M | 58.5 M | 29.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
11.9 M | 24.5 M | 46.2 M | 11.9 M | 85.1 M | 121 M | 115 M | 85.1 M | 3.4 M | 18.1 M | 7.32 M | 3.4 M | 4.66 M | 5.82 M | 6.53 M | 4.66 M | 4.47 M | 3.56 M | 35.6 M | 4.47 M | 4.47 M | 3.56 M | 20.2 M | 6.15 M | 6.15 M | 9.13 M | 13 M | 14.3 M | 24.1 M | 25.7 M | 21.3 M | 24.1 M | 33 M | 17.1 M | 32 M | 33 M | 17.1 M | 32 M | 7.19 M | 13.8 M | 1.54 M | 1.74 M | 4.22 M | - | - | - | 4.35 M | - | - | - | - |
Book Value |
-209 M | -182 M | -151 M | -209 M | -126 M | -85.3 M | -61.2 M | -126 M | 7.67 M | 33.7 M | -30.2 M | 2.24 M | 18.1 M | -46.9 M | -21.2 M | 18.1 M | 24.7 M | -14.7 M | -36.2 M | 24.7 M | -14.7 M | -36.2 M | -14.6 M | 3.82 M | 3.82 M | -16.4 M | 4.47 M | -5.08 M | 26.1 M | 9.66 M | -8.36 M | 26.1 M | -7.94 M | 9.9 M | 23.4 M | -7.94 M | 9.9 M | 23.4 M | -773 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-209 M | -182 M | -151 M | -209 M | -126 M | -85.3 M | -61.2 M | -126 M | 7.67 M | 33.7 M | -30.2 M | 2.24 M | 18.1 M | -46.9 M | -21.2 M | 18.1 M | 24.7 M | -14.7 M | -36.2 M | 24.7 M | 24.7 M | -14.7 M | -15.2 M | 3.82 M | 3.82 M | -16.4 M | 4.47 M | -5.08 M | 26.1 M | 9.66 M | -8.36 M | 26.1 M | -7.94 M | 9.9 M | 23.4 M | -7.94 M | 9.9 M | 23.4 M | -31.5 M | - | - | - | -23.1 M | - | - | - | -18.7 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Quotient Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | ||
|
Brainsway Ltd.
BWAY
|
$ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 13.46 | 1.05 % | $ 142 M | ||
|
Medpace Holdings
MEDP
|
$ 609.81 | -3.81 % | $ 17.6 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
- | - | $ 608 M | ||
|
RadNet
RDNT
|
$ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
IDEXX Laboratories
IDXX
|
$ 675.24 | -2.09 % | $ 54.3 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
$ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
$ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
$ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
$ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
$ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
$ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
$ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
$ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
$ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
$ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
$ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
$ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
$ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
$ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
$ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
$ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
$ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | ||
|
Biomerica
BMRA
|
$ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
$ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
$ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
$ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
$ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
$ 186.79 | -1.88 % | $ 14.6 B |